iTeos Belgium SA
9
0
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
22.2%
2 terminated/withdrawn out of 9 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
Role: lead
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Role: collaborator
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Role: collaborator
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Role: collaborator
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
Role: collaborator
First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
Role: collaborator
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
Role: collaborator
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Role: lead
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
Role: collaborator
All 9 trials loaded